Jan 07, 2025 7:00am EST iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Jan 02, 2025 7:00am EST iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Sep 20, 2024 4:05pm EDT iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Aug 12, 2024 4:30pm EDT iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
